SBIR Phase II: In vivo Fluorescence Imaging Kit for Cell Proliferation.

SBIR II 期：用于细胞增殖的体内荧光成像试剂盒。

• 批准号: 1152557
• 负责人: Maryana Breitman
• 金额: $ 49.98万
• 依托单位: MBMR Biolabs Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1152557&HistoricalAwards=false
• 关键词: SBIR; Phase; II; vivo; Fluorescence

This Small Business Innovation Research (SBIR) Phase II project proposes to develop an in vivo fluorescent imaging kit for cell proliferation that addresses the need to study cell growth processes in real time. Proof-of-concept has been demonstrated for a novel method of imaging DNA replication in vivo that is non-toxic and does not interfere with cellular metabolic processes. The method utilizes the unique specificity and high rate of reaction of bio-orthogonal ligation chemistry, and it has shown that in vivo labeling of DNA molecules with this novel bio-orthogonal mechanism yields fast, precise labeling of cell proliferation of cells in their natural environments. Most importantly, the method is minimally invasive, results in reliable incorporation of both the nucleotides and the label, and does not require cell lysis, DNA strand separations, or any of the abrasive treatments characteristic of cell proliferation assays currently on the market. The company plans to develop new methods for the usage of its technology with Fluorescently Activated Cell Sorting (FACS) protocols and testing different formats, such as tissues and different cell lines, for the applicability of this method.The broader impact/commercial potential of this project, if successful, is a Fluorescent Imaging Kit that can be routinely used with such advanced techniques as high content screening, high throughput screening for drug-discovery, and ADME-TOX assays, as well as with more traditional cell biology and molecular biology settings. The unique advantage of the proposed product is that it allows cell monitoring over prolonged time periods, up to several days. The product will have applications in multiple scientific disciplines, from cancer biology to stem cell biology, and streamline experimental protocols. The proposed assays are especially tailored to be fully compatible with high content screening, one of the major technologies at the forefront of personalized medicine, most notably in the field of oncology, and as such it will directly contribute to the advancement of new therapies, better diagnostics, and more efficient treatment plans. The method also will allow cutting costs of reagents by eliminating the need to repeat experiments multiple times to monitor different markers, and by streamlining research aspects of early stage drug discovery.

这个小企业创新研究（SBIR）第二阶段项目提出开发一种用于细胞增殖的体内荧光成像试剂盒，以满足真实的时间研究细胞生长过程的需要。概念验证已被证明是一种新的方法，在体内成像DNA复制是无毒的，不干扰细胞代谢过程。该方法利用了生物正交连接化学的独特特异性和高反应速率，并且已经表明，用这种新的生物正交机制在体内标记DNA分子产生了在其自然环境中细胞增殖的快速、精确标记。最重要的是，该方法是微创的，导致核苷酸和标记的可靠掺入，并且不需要细胞裂解、DNA链分离或目前市场上细胞增殖测定的任何研磨处理特征。该公司计划开发新的方法，用于使用其技术与荧光激活细胞分选（FACS）协议和测试不同的格式，如组织和不同的细胞系，为这种方法的适用性。更广泛的影响/商业潜力，这个项目，如果成功，是一个荧光成像试剂盒，可以常规使用这样的先进技术，如高含量筛选，用于药物发现的高通量筛选和ADME-TOX测定，以及更传统的细胞生物学和分子生物学设置。拟议产品的独特优势是它允许在长达几天的时间内进行细胞监测。该产品将应用于多个科学学科，从癌症生物学到干细胞生物学，并简化实验方案。所提出的检测方法经过特别定制，可与高含量筛选完全兼容，高含量筛选是个性化医疗最前沿的主要技术之一，尤其是在肿瘤学领域，因此它将直接有助于新疗法的发展，更好的诊断和更有效的治疗计划。该方法还将通过消除多次重复实验以监测不同标记物的需要以及简化早期药物发现的研究方面来降低试剂成本。